studies

mML - 1st line (L1), immune chekpoint inhibitors vs. Standard of Care (SoC), meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsA3671009, 2013 0.88 [0.75; 1.04] IMspire-150 (BRAF mutant), 2020 0.85 [0.65; 1.12] 0.87[0.76; 1.00]A3671009, 2013, IMspire-150 (BRAF mutant), 202020%1,169moderatenot evaluable progression or deaths (PFS)detailed resultsIMspire-150 (BRAF mutant), 2020 0.78 [0.63; 0.97] 0.78[0.63; 0.97]IMspire-150 (BRAF mutant), 202010%514NAnot evaluable objective responses (ORR)detailed resultsA3671009, 2013 1.14 [0.69; 1.88] IMspire-150 (BRAF mutant), 2020 1.19 [0.83; 1.71] 1.17[0.87; 1.57]A3671009, 2013, IMspire-150 (BRAF mutant), 202020%1,169lownot evaluable AE (any grade)detailed resultsA3671009, 2013 2.22 [1.12; 4.38] 2.22[1.12; 4.38]A3671009, 201310%644NAnot evaluable AE (grade 3-4)detailed resultsA3671009, 2013 1.84 [1.35; 2.52] 1.84[1.35; 2.52]A3671009, 201310%644NAnot evaluable AE leading to death (grade 5)detailed resultsA3671009, 2013 1.71 [0.85; 3.45] IMspire-150 (BRAF mutant), 2020 1.23 [0.42; 3.56] 1.55[0.86; 2.78]A3671009, 2013, IMspire-150 (BRAF mutant), 202020%1,155moderatenot evaluable AE leading to treatment discontinuation (any grade)detailed resultsA3671009, 2013 97.13 [5.95; 1585.40] IMspire-150 (BRAF mutant), 2020 0.78 [0.47; 1.29] 7.09[0.06; 791.12]A3671009, 2013, IMspire-150 (BRAF mutant), 2020291%1,155lownot evaluable SAE (any grade)detailed resultsA3671009, 2013 3.19 [2.19; 4.65] 3.19[2.19; 4.65]A3671009, 201310%644NAnot evaluable STRAE (any grade)detailed resultsIMspire-150 (BRAF mutant), 2020 1.24 [0.85; 1.81] 1.24[0.85; 1.81]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable TRAE (any grade)detailed resultsIMspire-150 (BRAF mutant), 2020 0.82 [0.11; 5.85] 0.82[0.11; 5.85]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 1.41 [0.93; 2.12] 1.41[0.93; 2.12]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable TRAE leading to death (grade 5)detailed resultsA3671009, 2013 7.00 [0.86; 57.23] 7.00[0.86; 57.23]A3671009, 201310%644NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsA3671009, 2013 5.93 [0.30; 118.96] 5.93[0.30; 118.96]A3671009, 201310%644NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 1.44 [0.48; 4.34] 1.44[0.48; 4.34]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 2.47 [0.45; 13.60] 2.47[0.45; 13.60]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 0.61 [0.02; 18.27] 0.61[0.02; 18.27]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Chorioretinopathy TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 0.61 [0.02; 18.27] 0.61[0.02; 18.27]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 0.30 [0.01; 6.77] 0.30[0.01; 6.77]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 0.53 [0.16; 1.76] 0.53[0.16; 1.76]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Dry skin TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67] 4.92[0.22; 109.67]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Erythema TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 7.41 [0.37; 148.78] 7.41[0.37; 148.78]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Eye disorders TRAE (grade 3-4)detailed resultsA3671009, 2013 0.98 [0.02; 49.62] 0.98[0.02; 49.62]A3671009, 201310%644NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 3.70 [0.38; 35.82] 3.70[0.38; 35.82]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsA3671009, 2013 3.94 [0.18; 87.81] 3.94[0.18; 87.81]A3671009, 201310%644NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67] 4.92[0.22; 109.67]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 0.99 [0.64; 1.52] 0.99[0.64; 1.52]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 1.36 [0.78; 2.37] 1.36[0.78; 2.37]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 2.46 [0.22; 27.26] 2.46[0.22; 27.26]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 0.17 [0.02; 1.40] 0.17[0.02; 1.40]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsA3671009, 2013 5.93 [0.30; 118.96] 5.93[0.30; 118.96]A3671009, 201310%644NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 1.22 [0.02; 61.84] 1.22[0.02; 61.84]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67] 4.92[0.22; 109.67]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 2.46 [0.22; 27.26] 2.46[0.22; 27.26]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 1.22 [0.24; 6.13] 1.22[0.24; 6.13]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Rash TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 0.98 [0.53; 1.81] 0.98[0.53; 1.81]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 0.48 [0.09; 2.52] 0.48[0.09; 2.52]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsA3671009, 2013 4.04 [1.13; 14.45] 4.04[1.13; 14.45]A3671009, 201310%644NAnot evaluable Asthenia AE (grade 3-4)detailed resultsA3671009, 2013 0.10 [0.01; 1.78] 0.10[0.01; 1.78]A3671009, 201310%644NAnot evaluable Constipation AE (grade 3-4)detailed resultsA3671009, 2013 0.98 [0.14; 7.01] 0.98[0.14; 7.01]A3671009, 201310%644NAnot evaluable Cough AE (grade 3-4)detailed resultsA3671009, 2013 1.97 [0.07; 58.81] 1.97[0.07; 58.81]A3671009, 201310%644NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsA3671009, 2013 14.32 [1.87; 109.52] 14.32[1.87; 109.52]A3671009, 201310%644NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsA3671009, 2013 4.00 [0.84; 18.98] 4.00[0.84; 18.98]A3671009, 201310%644NAnot evaluable Fatigue AE (grade 3-4)detailed resultsA3671009, 2013 3.90 [1.44; 10.57] 3.90[1.44; 10.57]A3671009, 201310%644NAnot evaluable Headache AE (grade 3-4)detailed resultsA3671009, 2013 1.97 [0.18; 21.82] 1.97[0.18; 21.82]A3671009, 201310%644NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsIMspire-150 (BRAF mutant), 2020 1.22 [0.02; 61.84] 1.22[0.02; 61.84]IMspire-150 (BRAF mutant), 202010%511NAnot evaluable Nausea AE (grade 3-4)detailed resultsA3671009, 2013 1.39 [0.61; 3.18] 1.39[0.61; 3.18]A3671009, 201310%644NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsA3671009, 2013 0.03 [0.00; 0.19] 0.03[0.00; 0.19]A3671009, 201310%644NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsA3671009, 2013 4.97 [0.58; 42.77] 4.97[0.58; 42.77]A3671009, 201310%644NAnot evaluable Pruritus AE (grade 3-4)detailed resultsA3671009, 2013 5.93 [0.30; 118.96] 5.93[0.30; 118.96]A3671009, 201310%644NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsA3671009, 2013 7.94 [0.42; 150.76] 7.94[0.42; 150.76]A3671009, 201310%644NAnot evaluable Rash AE (grade 3-4)detailed resultsA3671009, 2013 7.00 [0.86; 57.23] 7.00[0.86; 57.23]A3671009, 201310%644NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsA3671009, 2013 0.03 [0.00; 0.26] 0.03[0.00; 0.26]A3671009, 201310%644NAnot evaluable Vomiting AE (grade 3-4)detailed resultsA3671009, 2013 1.55 [0.66; 3.64] 1.55[0.66; 3.64]A3671009, 201310%644NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsA3671009, 2013 0.98 [0.06; 15.76] 0.98[0.06; 15.76]A3671009, 201310%644NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-10-05 15:02 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 285,68,127,128 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons